3-N-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)-3-aminobenzoic acid | 246135-56-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-N-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)-3-aminobenzoic acid
• 英文别名: 3-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-ylamino)benzoic acid；3-[(5-Hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoic acid
• CAS: 246135-56-8
• 化学式: C₁₁H₁₃N₃O₃
• 分子量: 235.243
• InChiKey: JZEFJPMPIPCNBI-UHFFFAOYSA-N

物化性质

• 沸点：
  465.2±55.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  94
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-N-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)-3-aminobenzoic acid 在 lithium hydroxide 、 1-羟基苯并三唑 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 21.5h， 生成 (3R)-3-(5-bromo-3-chloro-2-hydroxyphenyl)-3-(2-(3-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-ylamino)benzamido)acetamido)propanoic acid
  参考文献：
  名称：

  R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors

  摘要：

  The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.034
• 作为产物：
  描述：

  1-(3-羧苯基)-2-硫脲 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 3-N-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)-3-aminobenzoic acid
  参考文献：
  名称：

  ALPHA-5 BETA-1 INHIBITORS

  摘要：

  该披露提供了包括alpha-5 beta-1抑制剂、含有alpha-5 beta-1抑制剂的药物组合物、使用alpha-5 beta-1抑制剂治疗疾病的方法，以及制备alpha-5 beta-1抑制剂的过程等内容。

  公开号：

  US20210171455A1

文献信息

• [EN] PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS<br/>[FR] COMPOSES DE PIPERIDINYLE LIANT SELECTIVEMENT LES INTEGRINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004020435A1

  公开（公告）日：2004-03-11

  The invention is directed to piperidinyl compounds of formula (I) and (II) that selectively bind integrin receptors and methods for treating an integrin mediated disorder, wherein W, R2, Z and q are described in the application.

  这项发明涉及选择性结合整合素受体的式(I)和(II)的哌啶基化合物，以及治疗整合素介导的疾病的方法，其中W、R2、Z和q在申请中有描述。
• ALPHA-5 BETA-1 INHIBITORS
  申请人：The Regents of the University of California

  公开号：US20210171455A1

  公开（公告）日：2021-06-10

  The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

  该披露提供了包括alpha-5 beta-1抑制剂、含有alpha-5 beta-1抑制剂的药物组合物、使用alpha-5 beta-1抑制剂治疗疾病的方法，以及制备alpha-5 beta-1抑制剂的过程等内容。
• [EN] THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] ISOMERE R DE COMPOSES D'ACIDES AMINES BETA EN TANT QUE DERIVES ANTAGONISTES DU RECEPTEUR DES INTEGRINES
  申请人：PHARMACIA CORPRATION

  公开号：WO2004060376A1

  公开（公告）日：2004-07-22

  The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the αV β5 integrin without significantly inhibiting the αV β6 integrin

  本发明涉及一类由公式(I)表示的化合物或其药用可接受的盐，包含公式(I)化合物的药物组合物，以及在不显著抑制αVβ6整合素的情况下选择性抑制或拮抗αVβ3和/或αVβ5整合素的方法。
• Piperidinyl compounds that selectively bind integrins
  申请人：De Corte Bart

  公开号：US20080058359A1

  公开（公告）日：2008-03-06

  The invention is directed to piperidinyl compounds that selectively bind integrin receptors and methods for treating an integrin mediated disorder.

  这项发明涉及选择性结合整合素受体的哌啶化合物以及治疗整合素介导疾病的方法。
• PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS
  申请人：De Corte Bart

  公开号：US20110092528A1

  公开（公告）日：2011-04-21

  The invention is directed to piperidinyl compounds that selectively bind integrin receptors and methods for treating an integrin mediated disorder.

  本发明涉及选择性结合整合素受体的哌啶化合物和治疗整合素介导的疾病的方法。